Anti-fibrillarin antibodies aid in the prediction of mortality, improve diagnostic accuracy, and can be useful in early diagnosis since autoantibodies are present in very early SSc before clinical symptoms appear [25–27]. This evidence concerns the gene FBL and systemic sclerosis.